Therapeutic Strategies and Oncological Outcome of Peritoneal Metastases from Lung Cancer: A Systematic Review and Pooled Analysis.
Leandro Siragusa, Sara Di Carlo, Alessia Fassari, Bruno Sensi, Camilla Riccetti, Luciano Izzo, Giuseppe Cavallaro, Enrico Fiori, Paolo Sapienza, Letizia Mallia, Graziano Pernazza, Simone Sibio
Author Information
Leandro Siragusa: Department of Surgical Sciences, University of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy. ORCID
Sara Di Carlo: Department of Surgical Sciences, University of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy. ORCID
Alessia Fassari: Department of Surgery, Sapienza University of Rome, "Umberto I" University Hospital, Viale del Policlinico 155, 00161 Rome, Italy. ORCID
Bruno Sensi: Department of Surgical Sciences, University of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy.
Camilla Riccetti: Department of Surgical Sciences, University of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy.
Luciano Izzo: Department of Surgery, Sapienza University of Rome, "Umberto I" University Hospital, Viale del Policlinico 155, 00161 Rome, Italy. ORCID
Giuseppe Cavallaro: Department of Surgery, Sapienza University of Rome, "Umberto I" University Hospital, Viale del Policlinico 155, 00161 Rome, Italy. ORCID
Enrico Fiori: Department of Surgical Sciences, University of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy. ORCID
Paolo Sapienza: Department of Surgery, Sapienza University of Rome, "Umberto I" University Hospital, Viale del Policlinico 155, 00161 Rome, Italy. ORCID
Letizia Mallia: Sapienza University of Rome-ASL Roma 6-Via borgo Garibaldi 12, Albano Laziale, 00041 Rome, Italy.
Graziano Pernazza: San Giovanni Hospital-Via dell'Amba Aradam 8, 00184 Roma, Italy. ORCID
Simone Sibio: Department of Surgery, Sapienza University of Rome, "Umberto I" University Hospital, Viale del Policlinico 155, 00161 Rome, Italy. ORCID
The peritoneum is an unusual site of metastases from lung cancer, and optimal management at the moment remains unclear and mostly based on palliative strategies. Therefore, the aim of the study was to investigate demographic characteristics, management and overall survival of patients with peritoneal metastases from lung cancer (PCLC). A PRISMA-compliant systematic review and pooled analysis was performed searching all English studies published until December 2022. PROSPERO, CRD42022349362. Inclusion criteria were original articles including patients with peritoneal carcinomatosis from lung cancer, specifying at least one outcome of interest. Exclusion criteria were being unable to retrieve patient data from articles, and the same patient series included in different studies. Among 1746 studies imported for screening, twenty-one were included (2783 patients). Mean overall survival was between 0.5 and 5 months after peritoneal carcinomatosis diagnosis and 9 and 21 months from lung cancer diagnosis. In total, 27% of patients underwent first-line or palliative chemotherapy and 7% of them surgery. Management differs significantly among published studies. The literature on PCLC is scarce. Its incidence is low but appears to be substantially rising and is likely to be an underestimation. Prognosis is very poor and therapeutic strategies have been limited and used in a minority of patients. Subcategories of PCLC patients may have an improved prognosis and may benefit from an aggressive oncological approach, including cytoreductive surgery. Further investigation would be needed in this regard.
